On the same day that Elixir Pharmaceuticals canned its IPO plans citing tough market conditions, Aldagen filed an S-1 expecting to raise as much as $81M. The company has not yet issued details of how many shares they expect to offer or even the share price. The only biotech, US IPO was Bioheart Inc.’s infinitesimal $5.8M offering in February.
In the S-1, the company said the proceeds from the offering would be used to fund ongoing research and development, including clinical trials. The company uses a platform to find adult stem cells expressing high levels of aldehyde dehydrogenase (ALDH), an enzyme believed to promote regeneration across a wide variety of cell types. Aldagen began enrolling patients in a phase III trial in March to improve the efficacy of umbilical cord blood transplants used to treat inherited metabolic diseases. Results are expected in the first half of 2010.
I doubt the Aldagen IPO will be any different that the nearly 20 other biotech IPO filings idling waiting for the market to change. After the Bioheart fiasco, it might be nice if Aldagen raised enough cash to pay Cowen its fees.
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)